---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-24-000162"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:09:26.841103+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GoodRx reports Q2 2024 revenue $200.6M, net income $6.7M, adjusted EBITDA $65.4M

## Summary
- Revenue and Adjusted Revenue of $200.6M for Q2 2024.
- Net income of $6.7M (3.3% margin); Adjusted Net Income of $32.4M (16.1% margin).
- Adjusted EBITDA of $65.4M (32.6% margin).
- Net cash from operations $9.7M; over 7M consumers of prescription offerings.
- Interim CEO Scott Wagner noted progress in retail/PBM partnerships and brand medication scaling.

## SEC filing metadata
- accession: 0001809519-24-000162
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000162/0001809519-24-000162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000162/gdrx-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-24-000162
- JSON: https://secwatch.observer/filing/0001809519-24-000162.json
- Plain text: https://secwatch.observer/filing/0001809519-24-000162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.